Literature DB >> 1957318

Formation of hemoglobin adducts of acrylamide and its epoxide metabolite glycidamide in the rat.

E Bergmark1, C J Calleman, L G Costa.   

Abstract

A method was developed for the determination of hemoglobin (Hb) adducts formed by the neurotoxic agent acrylamide and its mutagenic epoxide metabolite glycidamide. The method was based on simultaneous measurements of the cysteine adducts formed by these two agents by means of gas chromatography/mass spectrometry in hydrolyzed hemoglobin samples. Rats were injected ip with acrylamide or glycidamide in doses ranging from 0 to 100 mg/kg body wt, and the hemoglobin adduct levels were determined. The hemoglobin binding index of acrylamide to cysteine was found to be 6400 pmol (g Hb)-1/mumol (kg body wt)-1, higher than for any other substance studied so far in the rat, and 1820 pmol (g Hb)-1/mumol (kg body wt)-1 for glycidamide. In rats injected with acrylamide, formation of adducts of the parent compound was approximately linear with dose (0-100 mg/kg), whereas adducts of the epoxide metabolite glycidamide generated a concave curve, presumably reflecting the Michaelis-Menten kinetics of its formation. On the basis of the rate constants for cysteine adduct formation determined in vitro, the first-order rates of elimination of acrylamide and glycidamide from the blood compartment of rats were estimated to be 0.37 and 0.48 hr-1, respectively, using a linear kinetic model. It was further estimated that the percentage of acrylamide converted to glycidamide in the rat decreased from 51% following administration of 5 mg/kg to 13% after a dose of 100 mg/kg. Subchronic treatment of rats with acrylamide (10 mg/kg/day for 10 days or 3.3 mg/kg/day for 30 days) confirmed that the conversion rate of acrylamide to glycidamide, as determined from hemoglobin adduct formation, is higher at low-administered doses. These findings suggest that dose-rate effects may significantly affect risk estimates of this compound and that different low-dose extrapolation procedures should be employed for effects induced by the parent compound acrylamide and those induced by the metabolite glycidamide.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1957318     DOI: 10.1016/0041-008x(91)90036-e

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

1.  Characterization of Acrylamidase isolated from a newly isolated acrylamide-utilizing bacterium, Ralstonia eutropha AUM-01.

Authors:  Minseok Cha; Glenn H Chambliss
Journal:  Curr Microbiol       Date:  2010-09-25       Impact factor: 2.188

2.  Carcinogenicity of glycidamide in B6C3F1 mice and F344/N rats from a two-year drinking water exposure.

Authors:  Frederick A Beland; Greg R Olson; Maria C B Mendoza; M Matilde Marques; Daniel R Doerge
Journal:  Food Chem Toxicol       Date:  2015-09-30       Impact factor: 6.023

3.  Photoheterotrophic metabolism of acrylamide by a newly isolated strain of Rhodopseudomonas palustris.

Authors:  David A Wampler; Scott A Ensign
Journal:  Appl Environ Microbiol       Date:  2005-10       Impact factor: 4.792

Review 4.  Dietary acrylamide and human cancer: a systematic review of literature.

Authors:  Mandeep K Virk-Baker; Tim R Nagy; Stephen Barnes; John Groopman
Journal:  Nutr Cancer       Date:  2014-05-29       Impact factor: 2.900

Review 5.  Biomarker research in neurotoxicology: the role of mechanistic studies to bridge the gap between the laboratory and epidemiological investigations.

Authors:  L G Costa
Journal:  Environ Health Perspect       Date:  1996-03       Impact factor: 9.031

6.  LC/MS/MS Analysis of N-Terminal Protein Adducts with Improved Sensitivity: A Comparison of Selected Edman Isothiocyanate Reagents.

Authors:  Per Rydberg; Hans von Stedingk; Jörgen Magnér; Jonas Björklund
Journal:  Int J Anal Chem       Date:  2009-11-04       Impact factor: 1.885

7.  A nonlinear dosimetric model for hemoglobin adduct formation by the neurotoxic agent acrylamide and its genotoxic metabolite glycidamide.

Authors:  C J Calleman; E Bergmark; L G Stern; L G Costa
Journal:  Environ Health Perspect       Date:  1993-03       Impact factor: 9.031

8.  Parallelogram based approach for in vivo dose estimation of genotoxic metabolites in humans with relevance to reduction of animal experiments.

Authors:  Hitesh V Motwani; Cecilia Frostne; Margareta Törnqvist
Journal:  Sci Rep       Date:  2017-12-14       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.